These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Gluud LL; Vilstrup H; Morgan MY Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005 [TBL] [Abstract][Full Text] [Related]
12. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Agrawal A; Sharma BC; Sharma P; Sarin SK Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579 [TBL] [Abstract][Full Text] [Related]
13. Prophylaxis of hepatic encephalopathy: current and future drug targets. Maharshi S; Sharma BC Hepatol Int; 2024 Aug; 18(4):1096-1109. PubMed ID: 38492132 [TBL] [Abstract][Full Text] [Related]
14. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis. Prakash RK; Kanna S; Mullen KD Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578 [TBL] [Abstract][Full Text] [Related]
15. Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial. Wang JY; Bajaj JS; Wang JB; Shang J; Zhou XM; Guo XL; Zhu X; Meng LN; Jiang HX; Mi YQ; Xu JM; Yang JH; Wang BS; Zhang NP J Dig Dis; 2019 Oct; 20(10):547-556. PubMed ID: 31448533 [TBL] [Abstract][Full Text] [Related]